Morgan Stanley’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-51,324
| Closed | -$1.74M | – | 8463 |
|
|
2025
Q4 | $1.74M | Buy |
51,324
+29,228
| +132% | +$908K | ﹤0.01% | 4903 |
|
|
2025
Q3 | $570K | Buy |
22,096
+4,082
| +23% | +$53.4K | ﹤0.01% | 5448 |
|
|
2025
Q2 | $144K | Sell |
18,014
-28,539
| -61% | -$218K | ﹤0.01% | 5983 |
|
|
2025
Q1 | $454K | Sell |
46,553
-7,926
| -15% | -$77.9K | ﹤0.01% | 5371 |
|
|
2024
Q4 | $689K | Buy |
54,479
+16,074
| +42% | +$204K | ﹤0.01% | 5281 |
|
|
2024
Q3 | $618K | Sell |
38,405
-108,957
| -74% | -$2.2M | ﹤0.01% | 5302 |
|
|
2024
Q2 | $3.6M | Sell |
147,362
-90,805
| -38% | -$4.19M | ﹤0.01% | 4151 |
|
|
2024
Q1 | $17.1M | Sell |
238,167
-23,167
| -9% | -$3.22M | ﹤0.01% | 2864 |
|
|
2023
Q4 | $52M | Buy |
261,334
+166,095
| +174% | +$20.6M | ﹤0.01% | 2409 |
|
|
2023
Q3 | $12.7M | Sell |
95,239
-16,639
| -15% | -$2.72M | ﹤0.01% | 2902 |
|
|
2023
Q2 | $16.7M | Buy |
111,878
+15,106
| +16% | +$2.35M | ﹤0.01% | 2647 |
|
|
2023
Q1 | $14.2M | Buy |
96,772
+1,999
| +2% | +$404K | ﹤0.01% | 2804 |
|
|
2022
Q4 | $15M | Sell |
94,773
-1,761
| -2% | -$282K | ﹤0.01% | 2634 |
|
|
2022
Q3 | $18.6M | Sell |
96,534
-33,910
| -26% | -$6.41M | ﹤0.01% | 2264 |
|
|
2022
Q2 | $19M | Sell |
130,444
-1,551
| -1% | -$207K | ﹤0.01% | 2345 |
|
|
2022
Q1 | $23.2M | Buy |
131,995
+7,011
| +6% | +$1.32M | ﹤0.01% | 1953 |
|
|
2021
Q4 | $36.7M | Buy |
124,984
+29,516
| +31% | +$7.89M | ﹤0.01% | 1576 |
|
|
2021
Q3 | $23.7M | Buy |
95,468
+52,127
| +120% | +$13.8M | ﹤0.01% | 1911 |
|
|
2021
Q2 | $11M | Buy |
43,341
+35,893
| +482% | +$6.71M | ﹤0.01% | 2862 |
|
|
2021
Q1 | $1.32M | Sell |
7,448
-4,416
| -37% | -$728K | ﹤0.01% | 4553 |
|
|
2020
Q4 | $1.87M | Buy |
11,864
+11,612
| +4,608% | +$2.52M | ﹤0.01% | 4221 |
|
|
2020
Q3 | $65K | Sell |
252
-738
| -75% | -$164K | ﹤0.01% | 5617 |
|
|
2020
Q2 | $229K | Buy |
990
+963
| +3,567% | +$149K | ﹤0.01% | 5015 |
|
|
2020
Q1 | $5K | Sell |
27
-339
| -93% | -$77.2K | ﹤0.01% | 6220 |
|
|
2019
Q4 | $82K | Buy |
+366
| New | +$67.4K | ﹤0.01% | 5710 |
|
Morgan Stanley's RAPT Position: Q1 2026 in Review
Morgan Stanley sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 51,324 shares — an estimated $1.74M sold.
Morgan Stanley first reported a position in RAPT in Q4 2019 and held it in 25 quarters. The position peaked at $52M in Q4 2023. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Morgan Stanley reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Morgan Stanley sold 51,324 RAPT Therapeutics shares in Q1 2026, an estimated $1.74M.
- Morgan Stanley first reported a position in RAPT Therapeutics in Q4 2019 and held it in 25 quarters.
- Morgan Stanley's RAPT Therapeutics position peaked at $52M in Q4 2023.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.